Contribution de la mort immunogène à l'efficacité de la chimiothérapie anticancéreuse.

G. Kroemer; Sandy Adjemian; Mickaël Michaud; Isabelle Martins; Oliver Kepp; Abdul Qader Sukkurwala; Laurie Menger; Erika Vacchelli; Yuting Ma; Laurence Zitvogel

Contribution de la mort immunogène à l'efficacité de la chimiothérapie anticancéreuse.

G. Kroemer, Sandy Adjemian, Mickaël Michaud, Isabelle Martins, Oliver Kepp, Abdul Qader Sukkurwala, Laurie Menger, Erika Vacchelli, Yuting Ma, Laurence Zitvogel

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

2 Citations (Scopus)

Résumé

Immunogenic cell death, characterized by calreticulin exposure on the surface of the dying cell, release of the nuclear protein high mobility group box 1 (HMGB1), and release of ATP, enables stimulation of the immune system. We outlined the importance of this kind of cell death for the success of some anticancer chemotherapies. However, defects in the immunogenic cell death signalling pathway can lead to therapeutic failure, apparently because anticancer immune responses must contribute to the efficacy of chemotherapeutic regimens. These defects can be related to the therapy, the tumour cell, the host or the tumour-host interface. It is necessary to characterize these defects to restore and improve the efficacy of anticancer chemotherapies.

Titre traduit de la contribution	[Contributions of immunogenic cell death to the efficacy of anticancer chemotherapy].
langue originale	Français
Pages (de - à)	130-138; discussion 139-140
journal	Bulletin et mémoires de l'Académie royale de médecine de Belgique
Volume	166
Numéro de publication	3-4
état	Publié - 1 déc. 2011

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{61f6bd9830c4483bbfde92f56e789408,

title = "Contribution de la mort immunog{\`e}ne {\`a} l'efficacit{\'e} de la chimioth{\'e}rapie anticanc{\'e}reuse.",

abstract = "Immunogenic cell death, characterized by calreticulin exposure on the surface of the dying cell, release of the nuclear protein high mobility group box 1 (HMGB1), and release of ATP, enables stimulation of the immune system. We outlined the importance of this kind of cell death for the success of some anticancer chemotherapies. However, defects in the immunogenic cell death signalling pathway can lead to therapeutic failure, apparently because anticancer immune responses must contribute to the efficacy of chemotherapeutic regimens. These defects can be related to the therapy, the tumour cell, the host or the tumour-host interface. It is necessary to characterize these defects to restore and improve the efficacy of anticancer chemotherapies.",

author = "G. Kroemer and Sandy Adjemian and Micka{\"e}l Michaud and Isabelle Martins and Oliver Kepp and Sukkurwala, {Abdul Qader} and Laurie Menger and Erika Vacchelli and Yuting Ma and Laurence Zitvogel",

year = "2011",

month = dec,

day = "1",

language = "Fran{\c c}ais",

volume = "166",

pages = "130--138; discussion 139--140",

journal = "Bulletin et m{\'e}moires de l'Acad{\'e}mie royale de m{\'e}decine de Belgique",

issn = "0377-8231",

number = "3-4",

}

Contribution de la mort immunogène à l'efficacité de la chimiothérapie anticancéreuse. / Kroemer, G.; Adjemian, Sandy; Michaud, Mickaël et al.
Dans: Bulletin et mémoires de l'Académie royale de médecine de Belgique, Vol 166, Numéro 3-4, 01.12.2011, p. 130-138; discussion 139-140.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - Contribution de la mort immunogène à l'efficacité de la chimiothérapie anticancéreuse.

AU - Kroemer, G.

AU - Adjemian, Sandy

AU - Michaud, Mickaël

AU - Martins, Isabelle

AU - Kepp, Oliver

AU - Sukkurwala, Abdul Qader

AU - Menger, Laurie

AU - Vacchelli, Erika

AU - Ma, Yuting

AU - Zitvogel, Laurence

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Immunogenic cell death, characterized by calreticulin exposure on the surface of the dying cell, release of the nuclear protein high mobility group box 1 (HMGB1), and release of ATP, enables stimulation of the immune system. We outlined the importance of this kind of cell death for the success of some anticancer chemotherapies. However, defects in the immunogenic cell death signalling pathway can lead to therapeutic failure, apparently because anticancer immune responses must contribute to the efficacy of chemotherapeutic regimens. These defects can be related to the therapy, the tumour cell, the host or the tumour-host interface. It is necessary to characterize these defects to restore and improve the efficacy of anticancer chemotherapies.

AB - Immunogenic cell death, characterized by calreticulin exposure on the surface of the dying cell, release of the nuclear protein high mobility group box 1 (HMGB1), and release of ATP, enables stimulation of the immune system. We outlined the importance of this kind of cell death for the success of some anticancer chemotherapies. However, defects in the immunogenic cell death signalling pathway can lead to therapeutic failure, apparently because anticancer immune responses must contribute to the efficacy of chemotherapeutic regimens. These defects can be related to the therapy, the tumour cell, the host or the tumour-host interface. It is necessary to characterize these defects to restore and improve the efficacy of anticancer chemotherapies.

UR - http://www.scopus.com/inward/record.url?scp=84863272916&partnerID=8YFLogxK

M3 - Article

C2 - 22375493

AN - SCOPUS:84863272916

SN - 0377-8231

VL - 166

SP - 130-138; discussion 139-140

JO - Bulletin et mémoires de l'Académie royale de médecine de Belgique

JF - Bulletin et mémoires de l'Académie royale de médecine de Belgique

IS - 3-4

ER -